← Leaderboards
Michael Arthur Bruckman
Haima Therapeutics, Llc
$2,429,350
Attributed
$2,429,350
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,429,350 · 2
By mechanism
R44$2,129,415 · 1
R43$299,935 · 1
Top collaborators
No co-investigators on record.
Most similar at Haima Therapeutics, Llc
Same institution · by research overlap
- Ujjal Didar Singh Sekhon$944,676
Others in their field
Other Emerging Leaders on “Life”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Martha Hering · Westat, Inc.$57,098,843
Research focus
LifeMouse ModelIntravenousLarge Scale ProductionMimeticsMinorHigh RiskInnovationHemostatic FunctionIn VivoEnsureInfection RiskDoseBloodBlood PlateletsDesignAutoimmune DiseasesInjuryConsumptionHemorrhageHemostatic AgentsIn VitroAffectNanotechnology
Grant awards (5)
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$50,000
R44 · FY2025 · HL · contact PI
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$972,163
R44 · FY2024 · HL · contact PI
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$112,804
R44 · FY2024 · HL · contact PI
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$994,448
R44 · FY2023 · HL · contact PI
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$299,935
R43 · FY2019 · HL · contact PI